MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Cardiac Myosin Inhibitor

Search medical newsFind research, conditions and clinical updates
  • Home
  • Cardiac Myosin Inhibitor
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM and Complementary Trials
Posted inCardiology Clinical Updates news

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM and Complementary Trials

Posted by By MedXY 09/09/2026
Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.
Read More
Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study
Posted inCardiology news

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

Posted by By MedXY 06/28/2026
The FOREST-HCM long-term study confirms aficamten's efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.
Read More
Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy
Posted inCardiology Specialties

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

Posted by By MedXY 09/10/2025
A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).
Read More
Aficamten: A Breakthrough Oral Therapy for Obstructive Hypertrophic Cardiomyopathy Across Symptom Severity
Posted inCardiology Clinical Updates news Specialties

Aficamten: A Breakthrough Oral Therapy for Obstructive Hypertrophic Cardiomyopathy Across Symptom Severity

Posted by By MedXY 08/17/2025
Aficamten significantly improves exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM), demonstrating robust efficacy and safety in both mildly and severely symptomatic patients.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Beyond Abstinence: Multidisciplinary Approaches Enhance Long-Term Outcomes After Liver Transplantation for Alcohol-Associated Liver Disease
  • Assessing Accuracy and Utility of Melanoma Risk Prediction Models in an Australian Cohort
  • A Minimum Standard Set for Reporting Lymphatic Surgery Outcomes: What the Society of Lymphatic Surgery Consensus Means for Practice
  • Putting People First in ICU Care: ESICM’s 2026 Consensus on Human-Centred Partnership
  • Force Multiplication in Body Contouring: Enhancing Access and Conversion through Advanced Practice Provider Clinics
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top